ArticleOncology letters2012

Fighting cancer from different signalling pathways: Effects of the proteasome inhibitor Bortezomib in combination with the polo-like-kinase-1-inhibitor BI2536 in SCCHN.

Martin Leinung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.